Evidence map›Paper›PMID 40832543›Full record

ArticleACS medicinal chemistry letters2025

Discovery of an Aziridine-Based Inhibitor That Targets Cysteine Desulfurase Type II SufS via High-Throughput X‑ray Crystallography.

Takashi Fujishiro, Hono Otsuka, Ryosuke Nakamura, Takashi Fujihara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Takashi FujishiroDepartment of Biochemistry and Molecular Biology, Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan.ORCID https://orcid.org/0000-0001-7967-8380
Hono OtsukaDepartment of Biochemistry and Molecular Biology, Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan.
Ryosuke NakamuraDepartment of Biochemistry and Molecular Biology, Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan.
Takashi FujiharaComprehensive Analysis Center for Science, Saitama University, Saitama 338-8570, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structure-based drug design is an emerging technology for developing new drugs. However, in silico modeling and predicting inhibitors covalently bound to cofactor-containing enzymes remain challenging. Here, we demonstrate an alternative approach for visualizing protein inhibitor binding via X-ray crystallography of PLP-dependent enzyme crystals. Specifically, we used crystals of type II cysteine desulfurase, SufS, a drug-target enzyme in the iron-sulfur cluster biosynthetic SUF system. We identified (2

Indexed as

Aziridine-based inhibitorCysteine desulfuraseFe−S cluster biosynthesisStructure-based drug designSUF system

Identifiers

PMID40832543
PMCPMC12359001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.